Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 22Unknown 4Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 39Genitourinary 23Thoracic 11Breast 10Other hematologic neoplasm 8Lymphoid 4Sarcoma 3Head & Neck 3Endocrine 3Tumor-Agnostic 2Plasma cell 2Myeloid 2Gynecologic 2CNS 2Other solid neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Melanoma 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sorafenib × Dermatologic × Clear all
NCT00673361 2016-01-13

Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma

Duke University

Phase 2 Terminated
9 enrolled 3 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡